Treatment

SCENESSE 16 mg implant clinical trials

1 indexed studies · 0 currently recruiting

Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A Study to Evaluate the Pharmacokinetics of Afamelanotide in Patients with Erythropoietic Protoporphyria (EPP).
This study is looking at a medicine called SCENESSE to see how it moves through the body of adults with a rare skin condition called EPP. It aims to understand how much of the medicine stays in the body and for how long after treatment.
For: Erythropoietic Protoporphyria (EPP)
Belgium · Netherlands